Takeover Fever Struck Achillion, but AbbVie’s Still Way Out in Front
Insights - Achillion Pharmaceuticals (ACHN) has been all over the news in the last week (and up more than 100%), the latest target of takeover fever in … Continue Reading
Read nowSearch Results for achn
Another Big Day for Achillion, FDA Yellow-Lights Sovaprevir
Insights - Shares of Achillion Pharmaceuticals (ACHN) are up another 60% on Tuesday, adding to gains that coincided with Monday’s acquisition of fellow early HCV competitor, Idenix Pharmaceutical (IDIX). The stock is up 125% for … Continue Reading
Read now
Market Ripples from Merck’s Acquisition of Idenix
Insights - The announcement that Merck (MRK) plans to acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion, or $24.50 per share, is having a ripple effect on the … Continue Reading
Read nowEnanta Pharmaceuticals: Holding Ahead of Some Key Events
Long Ideas - Since our July 24 report on Enanta Pharmaceuticals (ENTA), shares of the HCV company have risen over 15%, even after accounting for the sell-off in … Continue Reading
Read nowFour Months After IPO, Enanta Pharmaceuticals Carries A Compelling Valuation Next to Hepatitis Peers
Long Ideas - Since making their market debut in March, shares of Enanta Pharmaceuticals (ENTA) have remained virtually flat, excluding a post-IPO pop (shares closed at $17.18 on … Continue Reading
Read nowHere Are Some of PropThink’s Top Healthcare Investments from The Last Week
Long Ideas - Curis (CRIS) has been around for quite some time with little to show for it but a significant long-term loss and some dud product candidates. … Continue Reading
Read nowRead PropThink’s Top Biotech Stories From This Past Week
Recap - Darapladib failed two mid-stage studies in 2008, yet GlaxoSmithKline (GSK) moved the cardiovascular drug into Phase III trials nonetheless. While most investors consider the large … Continue Reading
Read now